| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.2047-2927.2013.00085.X |
| P698 | PubMed publication ID | 23785019 |
| P2093 | author name string | A B Altay | |
| A Kadioğlu | |||
| M B Semerci | |||
| M D Balbay | |||
| M F Özcan | |||
| M K Çalişkan | |||
| M Ö Yaman | |||
| M Ortaç | |||
| S Çayan | |||
| T M Okutucu | |||
| P2860 | cites work | Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation | Q28274474 |
| Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms | Q33480753 | ||
| The worldwide prevalence and epidemiology of erectile dysfunction | Q34062787 | ||
| The International Index of Erectile Function (IIEF): a state-of-the-science review | Q34769477 | ||
| Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. | Q35759044 | ||
| Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. | Q35824111 | ||
| Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms | Q35876954 | ||
| Phosphodiesterase 11: a brief review of structure, expression and function | Q36361603 | ||
| Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects | Q36792665 | ||
| Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction | Q37321412 | ||
| PDE5 inhibitors: in vitro and in vivo pharmacological profile. | Q37622381 | ||
| Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010). | Q37929740 | ||
| A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus | Q38474381 | ||
| The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents | Q38492913 | ||
| The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences | Q40801831 | ||
| Health-related quality of life in men with erectile dysfunction | Q41190819 | ||
| Interrelationship of sildenafil treatment effects on the physiological and psychosocial aspects of erectile dysfunction of mixed or organic etiology | Q42971829 | ||
| Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial | Q43088938 | ||
| Prevalence and correlates of erectile dysfunction in Turkey: a population-based study | Q44103146 | ||
| Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction | Q44297429 | ||
| Pharmacokinetics of DA‐8159, a New Erectogenic, after Intravenous and Oral Administration to Rats: Hepatic and Intestinal First‐Pass Effects | Q44645961 | ||
| Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial | Q45194924 | ||
| Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile | Q45711327 | ||
| Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction | Q46537174 | ||
| The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction | Q46790499 | ||
| Attitudes of men with erectile dysfunction: a cross-national survey | Q47228040 | ||
| Sex therapy for erectile dysfunction: characteristics of couples, treatment outcome, and prognostic factors | Q48843302 | ||
| The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. | Q50951063 | ||
| Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. | Q53147807 | ||
| Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. | Q53155946 | ||
| Moderate and severe erectile dysfunction equally affects life satisfaction. | Q53245915 | ||
| Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. | Q53343954 | ||
| P433 | issue | 4 | |
| P921 | main subject | placebo | Q269829 |
| erectile dysfunction | Q184674 | ||
| P304 | page(s) | 549-555 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Andrology | Q26839702 |
| P1476 | title | Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study | |
| P478 | volume | 1 |
| Q43244521 | Commentary on - "Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunction". |
| Q38615555 | Erectile dysfunction and its management in patients with diabetes mellitus |
| Q47365660 | PDGF-mediated PI3K/AKT/β-catenin signaling regulates gap junctions in corpus cavernosum smooth muscle cells |
| Q90496815 | Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis |
| Q26851999 | Udenafil for the treatment of erectile dysfunction |
Search more.